RxDoctor Payments Data

Juan Bala, MD

Family Medicine · Spokane, WANPI 1043434681

Payments from drug & device makers

$2,071in general payments, 2019–2025

Across 31 payments — averaging $66.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$633
  • Novo Nordisk$522
  • Lilly USA, LLC$321
  • GSK$153
  • Amgen$125
  • Inspire Medical Systems, Inc.$122
  • plus $195 from 3 others

What the payments were for

  • Food & beverage$2,05399%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,071 in reported general payments places this provider in the 90th percentile of 2,275 family medicine providers in Washington.

See all family medicine providers in Washington

Medicare billing

Part B allowed, 2024
$99,156
Medicare patients
285
Services billed
2,305

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin57$67,119
OzempicSemaglutide49$61,817
EliquisApixaban75$57,734
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$48,063
XareltoRivaroxaban26$41,039
RybelsusSemaglutide22$26,172
TrulicityDulaglutide11$14,726
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$5,850
Omeprazole275$5,300
Albuterol Sulfate HfaAlbuterol Sulfate119$4,654
Atorvastatin Calcium394$4,622
Gabapentin154$3,875
Arnuity ElliptaFluticasone Furoate13$3,377
Lisinopril441$3,247
SynthroidLevothyroxine Sodium55$2,989

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$522$87,98971 claims
Boehringer IngelheimJardiance$633$67,11957 claims
GSKTrelegy Ellipta, Arnuity Ellipta$153$51,44048 claims
Lilly USA, LLCTrulicity$321$14,72611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,275 family medicine providers in Washington.

Other family medicine in Spokane

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →